Literature DB >> 17932574

Timing of bypass surgery in stable patients after acute myocardial infarction.

Ramya Raghavan1, Bruno S Benzaquen, Lawrence Rudski.   

Abstract

OBJECTIVES: To determine the optimal timing for bypass surgery in stable patients after acute myocardial infarction (MI).
BACKGROUND: Coronary artery bypass graft surgery (CABG) is a proven treatment for coronary artery disease. Because of the hypothesized risk of hemorrhagic transformation, it had become common practice to wait four to six weeks after MI. Recently, improvements in surgical and perioperative management, as well as an increase in pre-CABG in-hospital waiting times and excess burden on health care resources, have pushed surgeons to operate earlier. The optimal timing for a stable patient to undergo CABG after MI is unclear, because there have been no randomized trials to answer this question.
METHODS: The published literature comparing early versus late surgical revascularization procedures in stable post-MI patients was reviewed.
RESULTS: No randomized, prospective trials were found; however, several retrospective studies were identified. Most series examining Q wave MIs showed that mortality is higher in the early stages post-MI and progressively decreases with time post-MI. When studies examined non-Q wave MIs separately, there appeared to be less of a mortality difference between early and late surgical revascularization. There was a large disparity between the definitions of early surgery post-MI among the studies, some as early as 6 h and others up to eight days. Factors that increased mortality include abnormal left ventricular function and urgency of surgery, and some studies found risk models helpful to define increased risk after infarction. The possible increased risk of early surgery may be balanced against the potential for improved remodelling, improved quality of life and decreased hospital stay costs.
CONCLUSIONS: There is a need for a randomized, prospective trial examining the optimal timing for CABG in stable post-MI patients.

Entities:  

Mesh:

Year:  2007        PMID: 17932574      PMCID: PMC2651421          DOI: 10.1016/s0828-282x(07)70860-7

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  51 in total

1.  Revascularization after acute myocardial infarction.

Authors:  L L Creswell; M J Moulton; J L Cox; M Rosenbloom
Journal:  Ann Thorac Surg       Date:  1995-07       Impact factor: 4.330

2.  International comparison of waiting times for selected cardiovascular procedures.

Authors:  R J Carroll; S D Horn; B Soderfeldt; B C James; L Malmberg
Journal:  J Am Coll Cardiol       Date:  1995-03-01       Impact factor: 24.094

3.  Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery.

Authors:  S J Pocock; R A Henderson; A F Rickards; J R Hampton; S B King; C W Hamm; J Puel; W Hueb; J J Goy; A Rodriguez
Journal:  Lancet       Date:  1995-11-04       Impact factor: 79.321

4.  Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials.

Authors:  K B Michels; S Yusuf
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

5.  Surgical revascularization after acute myocardial infarction. Does timing make a difference?

Authors:  C F Sintek; T A Pfeffer; S Khonsari
Journal:  J Thorac Cardiovasc Surg       Date:  1994-05       Impact factor: 5.209

6.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

7.  Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling.

Authors:  Erberto Carluccio; Paolo Biagioli; Gianfranco Alunni; Adriano Murrone; Claudio Giombolini; Temistocle Ragni; Paolo N Marino; Gianpaolo Reboldi; Giuseppe Ambrosio
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

8.  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors:  M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.

Authors:  B Greenberg; M A Quinones; C Koilpillai; M Limacher; D Shindler; C Benedict; B Shelton
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

10.  Serial changes in left ventricular size after acute myocardial infarction.

Authors:  G Ertl; P Gaudron; C Eilles; K Kochsiek
Journal:  Am J Cardiol       Date:  1991-11-18       Impact factor: 2.778

View more
  3 in total

1.  Preoperative risk factors in 10 418 patients with prior myocardial infarction and 5241 patients with prior unstable angina undergoing elective coronary artery bypass graft surgery.

Authors:  A Bottle; A Mozid; H P Grocott; M R Walters; K R Lees; P Aylin; R D Sanders
Journal:  Br J Anaesth       Date:  2013-04-16       Impact factor: 9.166

Review 2.  Biologics and their delivery systems: Trends in myocardial infarction.

Authors:  Matthew A Borrelli; Heth R Turnquist; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-03-26       Impact factor: 17.873

3.  Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study.

Authors:  Huan Song; Fang Fang; Unnur Valdimarsdóttir; Donghao Lu; Therese M-L Andersson; Christina Hultman; Weimin Ye; Lars Lundell; Jan Johansson; Magnus Nilsson; Mats Lindblad
Journal:  BMC Cancer       Date:  2017-01-03       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.